Cardiomyopathy (Formulary) | Right Decisions

Right Decisions
TAM (Treatments and Medicines) NHS Highland
FORMULARIES
HIGHLAND FORMULARY
Back
CARDIOVASCULAR SYSTEM
Cardiomyopathy (Formulary)

Update your RDS mobile app to v4.7.2 to download toolkits even when website is down.

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. You will see that each toolkit has a small QR code icon in the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively update to the latest release - RDS app version 4.7.1 - to see this improvement.

Updating to this latest version of the RDS app is also strongly recommended to get the full benefits of the new resilience arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits. To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

What's new / Latest updates

04/11/24 - Mavacamten capsules 2.5mg, 5mg, 10mg, 15mg added for SMC2618 indication.

MAVACAMTEN

Important: Therapy notes

Bioequivalence between different capsule strengths has not been confirmed, therefore only one capsule of the appropriate strength should be used to achieve the prescribed dose and not multiple capsules. See: mavacamten.
A patient card and patient guide should be provided: Camzyos 15mg hard capsules - Risk Management Materials.

Important: Formulation and dosage details

Formulation:

Capsules 2.5mg, 5mg, 10mg, 15mg (Restricted: Hospital use only)

Dosage:

As per SMC2618: for the treatment of symptomatic (New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.

Responsibilities

Specialist team:

Pre-treatment screening, as per BNF
Monitoring requirements, as per BNF
Clinical review and planned treatment cessation

Primary care team (when the medicine becomes available):

Maintenance prescribing under the direction of the specialist team

Last reviewed: 31/10/2024

Next review date: 30/11/2025

Document Id: F393